In the original article, all references for in Tables 1, 2 were incorrectly listed. The corrected references for both Table 1 and Table 2 have been corrected and provided below.
Table 1
| Event | Mediated by | References |
|---|---|---|
| MITOCHONDRIAL METABOLISM | ||
| Increased oxidative phosphorylation | Down regulation of Drp1 | (61) |
| HuR | (50) | |
| Increased biogenesis | HuR | Unpublished |
| NUTRIENT ACQUISITION | ||
| Autophagy | Oncogenic KRAS | (74) |
| NAD+ salvage pathway | miR-206 | (78, 79) |
| Macropinocytosis | Oncogenic KRAS | (35) |
| Increased alanine uptake | Oncogenic KRAS | (85) |
| REDOX HOMEOSTASIS | ||
| Upregulation of ME1 | Oncogenic KRAS | (57) |
| Upregulation of NRF2 | Oncogenic KRAS | (97) |
| Upregulation of IDH1 | HuR | (50) |
Metabolic dependencies in PDA.
Table 2
| Target | Agent | Phase and status | NCT No. | References |
|---|---|---|---|---|
| MITOCHONDRIAL OXPHOS | ||||
| ETC | Metformin + gemcitabine + ertotinib | II; Completed | NCT01210911 | (63) |
| Metformin + paclitaxel | II; Completed | NCT01971034 | (103) | |
| Metformin + gemcitabine/nab-paclitaxel | I; Recruiting | NCT02336087 | ||
| Metformin + mFOLFIRINOX | II; Active | NCT01666730 | ||
| Metformin + rapamycin | Ib; Active | NCT02048384 | ||
| Metformin + radiosurgery | I; Active | NCT02153450 | ||
| TCA cycle | CPI-613 | I; Completed | NCT01839981 | |
| CPI-613 + mFOLFIRINOX | I; Active | NCT01835041 | (67) | |
| CPI-613 + gemcitabine/nab-paclitaxel | I; Active | NCT03435289 | ||
| NUTRIENT ACQUISITION | ||||
| Autophagy | HCQ | II; Completed | NCT01273805 | (104) |
| HCQ + gemcitabine | I/II; Active | NCT01128296 | ||
| HCQ + gemcitabine + abraxane | I/II; Active | NCT01506973 | ||
| CQ + gemcitabine | I; Completed | NCT01777477 | (105, 106) | |
| REDOX HOMEOSTASIS | ||||
| Glutaminase | CB-839 | I; Active | NCT02071862 | |
Clinical trials targeting key steps of PDA metabolism.
HCQ, hydroxychloroquine; CQ, chloroquine; mFOLFIRINOX, modified FOLFIRINOX.
In the original article, references in Table 2 were not provided in the reference list. The references have now been inserted.
The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.
References
35.
CommissoCDavidsonSMSoydaner-AzelogluRGParkerSJKamphorstJJHackettSet al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature (2013) 497:633–7. 10.1038/nature12138
50.
ZareiMLalSParkerSJNevlerAVaziri-GoharADukleskaKet al. Posttranscriptional upregulation of IDH1 by HuR establishes a powerful survival phenotype in pancreatic cancer cells. Cancer Res. (2017) 77:4460–71. 10.1158/0008-5472.CAN-17-0015
57.
SonJLyssiotisCAYingHWangXHuaSLigorioMet al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature (2013) 496:101–5. 10.1038/nature12040
61.
RamboldASKosteleckyBEliaNLippincott-SchwartzJ. Tubular network formation protects mitochondria from autophagosomal degradation during nutrient starvation. Proc Natl Acad Sci USA. (2011) 108:10190–5. 10.1073/pnas.1107402108
63.
KordesSPollakMNZwindermanAHMathotRAWetermanMJBeekerAet al. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. (2015) 16:839–47. 10.1016/S1470-2045(15)00027-3
67.
AlistarAMorrisBBDesnoyerRKlepinHDHosseinzadehKClarkCet al. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol. (2017) 18:770–8. 10.1016/S1470-2045(17)30314-5
74.
YangSWangXContinoGLiesaMSahinEYingHet al. Pancreatic cancers require autophagy for tumor growth. Genes Dev. (2011) 25:717–29. 10.1101/gad.2016111
78.
JuHQZhuangZNLiHTianTLuYXFanXQet al. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer. Cancer Lett. (2016) 379:1–11. 10.1016/j.canlet.2016.05.024
79.
ChiniCCGuerricoAMNinVCamacho-PereiraJEscandeCBarbosaMTet al. Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors. Clin Cancer Res. (2014) 20:120–30. 10.1158/1078-0432.CCR-13-0150
85.
SousaCMBiancurDEWangXHalbrookCJShermanMHZhangLet al. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature (2016) 536:479–83. 10.1038/nature19084
97.
DeNicolaGMKarrethFAHumptonTJGopinathanAWeiCFreseKet al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature (2011) 475:106–9. 10.1038/nature10189
103.
BraghiroliMIde Celis FerrariACPfifferTEAlexAKNebuloniDCarneiroASet al. Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas. Ecancermedicalscience (2015) 9:563. 10.3332/ecancer.2015.563
104.
WolpinBMRubinsonDAWangXChanJAClearyJMEnzingerPCet al. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist (2014) 19:637–8. 10.1634/theoncologist.2014-0086
105.
BalicASørensenMDTrabuloSMSainzBCioffiMVieiraCRet al. Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling. Mol Cancer Ther. (2014) 13:1758–71. 10.1158/1535-7163.MCT-13-0948
106.
SamarasPTusupMNguyen-KimTDLSeifertBBachmannHvon MoosRet al. Phase I study of a chloroquine-gemcitabine combination in patients with metastatic or unresectable pancreatic cancer. Cancer Chemother Pharmacol. (2017) 80:1005–12. 10.1007/s00280-0173446-y
Summary
Keywords
pancreatic cancer, metabolism, redox homeostasis, metabolic dependencies, targeting metabolism
Citation
Vaziri-Gohar A, Zarei M, Brody JR and Winter JM (2019) Corrigendum: Metabolic Dependencies in Pancreatic Cancer. Front. Oncol. 8:672. doi: 10.3389/fonc.2018.00672
Received
19 December 2018
Accepted
20 December 2018
Published
31 January 2019
Approved by
Frontiers in Oncology Editorial Office, Frontiers Media SA, Switzerland
Volume
8 - 2018
Updates
Copyright
© 2019 Vaziri-Gohar, Zarei, Brody and Winter.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jordan M. Winter jordan.winter@UHhospitals.org
This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.